• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Mylan

Mylan

Lord Abbett Small Cap Value R3 LRSRX 3 Star

Last Price$21.07Day Change (%)-0.52%
Open Price$21.07Day Change ($)-0.11
Day Range21.07–21.0752-Week Range19.92–24.75

As of Mon 04/24/2017 | USD

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  5. Research
  1. Here's how much Mylan's U.S. EpiPen recall could cost it

    Here's how much Mylan's U.S. EpiPen recall could cost it

  2. UPDATE: Here's how much Mylan's U.S. EpiPen recall could cost it

    UPDATE: Here's how much Mylan's U.S. EpiPen recall could cost it

  3. Hagens Berman: EpiPen Purchasers Accuse Drug Maker Mylan of Fraud, RICO Enterprise in National Class-Action Lawsuit over EpiPen Pricing

    Hagens Berman: EpiPen Purchasers Accuse Drug Maker Mylan of Fraud, RICO Enterprise in National Class-Action Lawsuit over EpiPen Pricing

  4. UPDATE: Mylan's EpiPen recall likely to have low U.S. revenue impact: EvercoreISI analyst

    UPDATE: Mylan's EpiPen recall likely to have low U.S. revenue impact: EvercoreISI analyst

  5. Global Atopic Dermatitis Drugs Market 2017-2021 with LEO Pharma, Mylan , Valeant, Bayer HealthCare & Encore Dermatology Dominating - Research and Markets

    Global Atopic Dermatitis Drugs Market 2017-2021 with LEO Pharma, Mylan , Valeant, Bayer HealthCare & Encore Dermatology Dominating - Research and Markets

  6. Mylan stock slumps 1.3% after company says voluntary recall will include U.S. EpiPens

    Mylan stock slumps 1.3% after company says voluntary recall will include U.S. EpiPens

  7. UPDATE: Mylan stock sinks 2% after FDA fails to approve its generic asthma medication

    UPDATE: Mylan stock sinks 2% after FDA fails to approve its generic asthma medication

  8. Global $228.8 Billion Generic Drugs Market 2017-2022 - Key Players are Freseunis, Hospira, Mylan , Novartis, Sandoz & Teva Pharmaceuticals - Research and Markets

    Global $228.8 Billion Generic Drugs Market 2017-2022 - Key Players are Freseunis, Hospira, Mylan , Novartis, Sandoz & Teva Pharmaceuticals - Research and Markets

  9. Rate Hikes? Not in 2015

    Watson Pharmaceuticals WPI scored big Tuesday when the Food and Drug Administration approved the firm's generic fentanyl patch. We may modestly increase our fair value estimate for Watson and will maintain our fair value estimate for competitor Mylan Laboratories MYL . The pain patch is one of the ...

  10. What Migration Can (and Can’t) Do for a Country’s GDP

    Mylan Laboratories MYL reported impressive second-quarter results Wednesday. However, most of the improvement was temporary and will not affect our fair value estimate. The quarter was only slightly better than we expected after excluding a one-time litigation payment and proceeds from a product ...

12345

©2017 Morningstar Advisor. All right reserved.